Current and investigational medications for the treatment of sarcopenia - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Metabolism Année : 2023

Current and investigational medications for the treatment of sarcopenia

Résumé

Sarcopenia, defined as the loss of muscle mass and function, is a widely prevalent and severe condition in older adults. Since 2016, it is recognized as a disease. Strength exercise training and nutritional support are the frontline treatment of sarcopenia, with no drug currently approved for this indication. However, new therapeutic options are emerging. In this review, we evidenced that only very few trials have focused on sarcopenia/sarcopenic patients. Most drug trials were performed in different clinical older populations (e.g., men with hypogonadism, post-menopausal women at risk for osteoporosis), and their efficacy were tested separately on the components of sarcopenia (muscle mass, muscle strength and physical performances). Results from trials testing the effects of Testosterone, Selective Androgen Receptor Modulators (SARMs), Estrogen, Dehydroepiandrosterone (DHEA), Insulin-like Growth Factor-1 (IGF-1), Growth Hormone (GH), GH Secretagogue (GHS), drug targeting Myostatin and Activin receptor pathway, Vitamin D, Angiotensin Converting Enzyme inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs), or β-blockers, were compiled. Although some drugs have been effective in improving muscle mass and/or strength, this was not translated into clinically relevant improvements on physical performance. Finally, some promising molecules investigated in on-going clinical trials and in pre-clinical phase were summarized, including apelin and irisin.
Fichier non déposé

Dates et versions

hal-04485773 , version 1 (01-03-2024)

Identifiants

Citer

Yves Rolland, Cedric Dray, Bruno Vellas, Philipe de Souto Barreto. Current and investigational medications for the treatment of sarcopenia. Metabolism, 2023, 149, pp.155597. ⟨10.1016/j.metabol.2023.155597⟩. ⟨hal-04485773⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More